CND to present updates from three clinical trials involving their skin biopsy diagnostic tool for dementia and other related disorders
CND Life Sciences (CND) announced that three abstracts related to changes in cutaneous phosphorylated alpha-synuclein (P-SYN) in patients with dementia with Lewy bodies (DLB) and other related disorders will be presented at the American Academy of Neurology 2025 Annual Meeting (AAN) from April 5-9 at the San Diego Convention Center.
Christopher Gibbons, MD, FAAN, chief scientific officer and co-founder of CND Life Sciences and professor of Neurology at Harvard Medical School, served as the lead author on two studies, both designed to track changes over time in cutaneous P-SYN in patients with DLB using skin biopsies. At the AAN, Dr. Gibbons will present unblinded baseline data quantifying the deposition of P-SYN and blood P-Tau 217 in patients with suspected DLB and Alzheimer’s disease at the mild cognitive impairment stage. He will also report on another study demonstrating that quantitative measures of cutaneous deposition suggest an annual increase in P-SYN deposition of 52% in patients with DLB.
Additional research found that limiting skin biopsy protocols to fewer than three biopsies results in a clinically significant percentage of false negative tests that increase as diagnostic certainty decreases. Furthermore, the diagnostic discrimination of synuclein subtyping provided by deposition pattern and distribution is lost with fewer than three biopsies.
